• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    10/18/24 8:45:00 AM ET
    $BOXL
    $CLDI
    $GRRR
    Other Consumer Services
    Real Estate
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BOXL alert in real time by email

    ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Calidi: https://www.redchip.com/assets/access/cldi_access

    • Gorilla Technology: https://www.redchip.com/assets/access/grrr_access

    In an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the multi-billion-dollar oncology field.

    Jay Chandan, Chairman and CEO of Gorilla Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. With over 22 years of operational excellence and a portfolio of 29 granted patents globally, Gorilla has established itself as a leader in delivering transformative solutions that drive large-scale digital transformation. The company's advanced technologies, including edge AI, big data analytics, IoT security, and virtualization infrastructure, empower clients across critical sectors such as government, public safety, manufacturing, and energy management to create smarter, safer and more efficient environments. Gorilla's strong financial foundation, innovative technology, and strategic market expansion provide a solid basis for long-term value creation as it continues to lead in the global digital transformation landscape. Gorilla has buy ratings and a mean price target of $29.50 from three analysts.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    About Gorilla Technology Group Inc.

    Headquartered in London U.K., Gorilla is a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology. We provide a wide range of solutions, including, Smart City, Network, Video, Security Convergence and IoT, across select verticals of Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare and Education, by using AI and Deep Learning Technologies.

    Our expertise lies in revolutionizing urban operations, bolstering security and enhancing resilience. We deliver pioneering products that harness the power of AI in intelligent video surveillance, facial recognition, license plate recognition, edge computing, post-event analytics and advanced cybersecurity technologies. By integrating these AI-driven technologies, we empower Smart Cities to enhance efficiency, safety and cybersecurity measures, ultimately improving the quality of life for residents.

    For more information, please visit our website: https://www.gorilla-technology.com/

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    [email protected]

    --END--

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $BOXL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • When will the interviews with Calidi Biotherapeutics and Gorilla Technology air?

      The interviews with Calidi Biotherapeutics and Gorilla Technology will air on Bloomberg TV on October 19, 2024, at 7 p.m. Eastern Time.

    • What area of cancer treatment does Calidi Biotherapeutics focus on?

      Calidi Biotherapeutics specializes in oncolytic virotherapy, leveraging engineered viruses to target and destroy cancer cells, while also enhancing immune response to fight tumors.

    • What technologies does Gorilla Technology Group specialize in?

      Gorilla Technology Group is a leader in digital solutions, particularly in edge AI, big data analytics, and IoT security, aimed at transforming operations in government, public safety, and manufacturing.

    • How does Calidi Biotherapeutics' technology differentiate itself in the oncology field?

      Calidi's unique approach involves using stem cell-based platforms that can carry oncolytic viruses, offering a safer and more efficient way to treat cancer.

    • What is the current analyst rating and price target for Gorilla Technology Group?

      Analysts have rated Gorilla Technology with buy ratings and have set a mean price target of $29.50.

    Recent Analyst Ratings for
    $BOXL
    $CLDI
    $GRRR

    CompanyDatePrice TargetRatingAnalyst
    Boxlight Corporation
    $BOXL
    11/14/2024Buy → Neutral
    Alliance Global Partners
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Calidi Biotherapeutics Inc.
    $CLDI
    10/9/2023$9.00Outperform
    Robert W. Baird
    Gorilla Technology Group Inc.
    $GRRR
    7/26/2023$4.80Overweight
    Cantor Fitzgerald
    Boxlight Corporation
    $BOXL
    12/13/2021$4.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BOXL
    $CLDI
    $GRRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Leftwich Scott

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:54 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Peoples George

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:56 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Schoeneck James A

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:59 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Boxlight downgraded by Alliance Global Partners

    Alliance Global Partners downgraded Boxlight from Buy to Neutral

    11/14/24 7:24:06 AM ET
    $BOXL
    Other Consumer Services
    Real Estate

    H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

    11/22/23 7:15:52 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

    Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

    10/9/23 7:23:07 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gorilla Technology Doubles Revenue in First Half of 2025 Amid International Expansion

    — Generated H1 2025 revenue of $39.3 million, representing 90.2% year-over-year growth —— Signed 3 new projects in Taiwan and UK —— Reduced debt to $18.1 million from $21.4 million at the end of 2024 and $18.4 million at the end of Q1 2025, strengthening financial flexibility and resilience —— Completed a $105 million equity offering in July 2025 to fund further growth opportunities —London, United Kingdom--(Newsfile Corp. - August 14, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, today reported its financial results for the first half ended

    8/14/25 8:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gorilla Technology Sets H1 2025 Conference Call for August 14 at 8:30 a.m. ET

    London, United Kingdom--(Newsfile Corp. - August 8, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company") will hold a conference call on Thursday, August 14, 2025, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) to discuss its financial results for the six months ended June 30, 2025. Financial results will be issued in a press release before the call.Call Date: Thursday, August 14, 2025 Time: 8:30 a.m. Eastern time (5:30 a.m. Pacific time) Toll Free: +1-833-752-4853International: +1-647-849-3362Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connect

    8/8/25 10:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $BOXL
    $CLDI
    $GRRR
    SEC Filings

    View All

    SEC Form S-1 filed by Calidi Biotherapeutics Inc.

    S-1 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    8/15/25 5:21:26 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Calidi Biotherapeutics Inc.

    SCHEDULE 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    8/14/25 9:05:27 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Gorilla Technology Group Inc.

    SCHEDULE 13G - Gorilla Technology Group Inc. (0001903145) (Subject)

    8/14/25 5:32:20 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $BOXL
    $CLDI
    $GRRR
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Gorilla Technology Group Appoints Bruce Bower as Chief Financial Officer

    London, United Kingdom--(Newsfile Corp. - May 14, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company"), a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence and IoT technology, is pleased to announce the appointment of Bruce Bower as Chief Financial Officer (CFO), effective 1 June 2025. Mr. Bower brings a wealth of experience in strategic financial management, capital raising and corporate governance. Since joining Gorilla as Interim CFO in September 2024, he has played a pivotal role in restructuring the Company's finance department, streamlining operations, and enhancing Gorilla's financial oversight and internal contr

    5/14/25 8:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

    4/25/25 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BOXL
    $CLDI
    $GRRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    12/6/24 9:25:12 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Gorilla Technology Group Inc.

    SC 13G/A - Gorilla Technology Group Inc. (0001903145) (Subject)

    9/17/24 6:53:48 PM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    $BOXL
    $CLDI
    $GRRR
    Financials

    Live finance-specific insights

    View All

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gorilla Technology Sets H1 2025 Conference Call for August 14 at 8:30 a.m. ET

    London, United Kingdom--(Newsfile Corp. - August 8, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company") will hold a conference call on Thursday, August 14, 2025, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time) to discuss its financial results for the six months ended June 30, 2025. Financial results will be issued in a press release before the call.Call Date: Thursday, August 14, 2025 Time: 8:30 a.m. Eastern time (5:30 a.m. Pacific time) Toll Free: +1-833-752-4853International: +1-647-849-3362Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connect

    8/8/25 10:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology

    Gorilla Technology Sets Q1 2025 Conference Call for June 18th, 2025, at 4:30 p.m. ET

    London, United Kingdom--(Newsfile Corp. - June 13, 2025) - Gorilla Technology Group Inc. (NASDAQ:GRRR) ("Gorilla" or the "Company") will hold a conference call on Wednesday, June 18th, 2025, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the first quarter of fiscal year 2025 ended March 31, 2025. Financial results will be issued in a press release before the call.Call Date: Wednesday, June 18th, 2025Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)Toll Free: +1-833-752-4853 International: +1-647-849-3362 Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you ha

    6/13/25 8:00:00 AM ET
    $GRRR
    Computer Software: Prepackaged Software
    Technology